Skip to main content
SleepCited

Cannabidiol Use in Inflammatory Bowel Disease: Insights From a Gastroenterology Outpatient Population.

Karina Fatakhova, Muhammad Jahanzaib Khan, Royce Perera, Sapphire Perera, Benjamin Glazebnik et al.
Other JGH open : an open access journal of gastroenterology and hepatology 2026
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D41958467'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Abstract

Cannabidiol (CBD) is increasingly used for symptom relief in chronic conditions, yet its role in inflammatory bowel disease (IBD) remains underexplored. We surveyed 229 IBD patients and found that 10.5% used CBD, primarily for anxiety (54.2%), insomnia (41.7%), and pain (41.7%). Among users, 87.5% perceived benefit. Most users were female, and one-third were on biologics. These findings highlight the growing interest in alternative therapies and the need for further research on CBD's safety, efficacy, and clinical guidance in IBD care.

Resumo Rápido

Surgeons surveyed 229 IBD patients and found that 10.5% used CBD, primarily for anxiety, primarily for anxiety, insomnia, and pain, and among users, 87.5% perceived benefit.

Used In Evidence Reviews

Similar Papers